Pfizer revealed they will add a third COVID-19 shot to trials for young children after the standard two-dose trial did not produce the desired results in some participants.
The company said Friday that, in a review of the data, the immune response benchmark “was met for the 6- to 24-month-old population but not for the 2- to under 5-year old population,” Just the News reports.
“The study will now include evaluating a third dose of 3 mg at least two months after the second dose of the two-dose series to provide high levels of protection in this young age group,” the statement said. “Pfizer and BioNTech also plan to evaluate a third dose of the 10 mg formulation in children 5 to under 12 years of age.”
